US · NRC · MEDICAL - HEALTHCARE INFORMATION SERVICES
NRC Health (NRC) intrinsic value and stock valuation
$25.16as of 2026-11-21 · Mkt cap 440.37M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
NRC Health DCF and intrinsic value
InvestorsCraft values NRC with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from NRC’s statements →
NRC Health Graham Number
Graham Number: $2.70d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $137.4M | $143.1M | $148.6M | $151.6M | $148M |
| Operating income | $22.6M | $35.2M | $40.1M | $46.5M | $50.3M |
| Net income | $11.6M | $24.8M | $31M | $31.8M | $37.5M |
| EPSd | $517.9K | $1.04M | $1.26M | $1.27M | $1.46M |
| Operating cash flow | $26.5M | $34.6M | $38.1M | $36.3M | $46.3M |
| Capital expenditure | -$-10.71M | -$-15.45M | -$-15.78M | -$-9.84M | -$-5.51M |
| Free cash flow | $15.7M | $19.2M | $22.3M | $26.4M | $40.8M |
| Total assets | $134.9M | $132.5M | $122.4M | $130.5M | $157.5M |
| Total debt | $79M | $64.4M | $39M | $23.4M | $28.7M |
| Net debt | $74.9M | $60.2M | $32.3M | -$-1.64M | -$-25.68M |
| Total equity | $14M | $31.3M | $49M | $72M | $85.3M |
| Cash and short-term investments | $4.14M | $4.23M | $6.65M | $25M | $54.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $137.4M | $143.1M | $148.6M | $151.6M | $148M |
| Cost of revenue | $60M | $56.9M | $56M | $57.1M | $52.4M |
| Gross profit | $77.4M | $86.1M | $92.6M | $94.5M | $95.6M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $54.8M | $44.9M | $46.6M | $42.7M | $39M |
| Other expenses | $0.00 | $6.02M | $5.94M | $5.28M | $6.37M |
| Operating expenses | $54.8M | $50.9M | $52.5M | $48M | $45.3M |
| Cost and expenses | $114.8M | $107.9M | $108.5M | $105M | $97.7M |
| Interest income | $110K | $120K | $820K | $170K | $10K |
| Interest expense | $4.76M | $2.6M | $860K | $1.21M | $1.67M |
| Depreciation and amortization | $7.62M | $6.02M | $5.9M | $5.28M | $6.37M |
| Ebitda | $30.2M | $41.3M | $46M | $49.3M | $56.7M |
| Operating income | $22.6M | $35.2M | $40.1M | $46.5M | $50.3M |
| Total other income/expenses, net | -$-4.75M | -$-2.5M | -$-80K | -$-3.73M | -$-1.65M |
| Income before tax | $17.8M | $32.7M | $40M | $42.8M | $48.6M |
| Income tax expense | $6.24M | $7.91M | $8.99M | $11M | $11.2M |
| Net income | $11.6M | $24.8M | $31M | $31.8M | $37.5M |
| Weighted average shares outstanding | $22.4M | $23.7M | $24.5M | $24.9M | $25.4M |
| Weighted average diluted shares outstanding | $22.4M | $23.7M | $24.7M | $25.1M | $25.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.14M | $4.23M | $6.65M | $25M | $54.4M |
| Net receivables | $11.6M | $11.2M | $12.6M | $15.3M | $14.6M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $20.2M | $19.6M | $24.4M | $43.7M | $73.7M |
| Property, plant and equipment, net | $40.5M | $39.9M | $30.3M | $17.8M | $13.4M |
| Goodwill and intangible assets | $68.4M | $68.8M | $63.1M | $63.2M | $63.4M |
| Long-term investments | $0.00 | $1.3M | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $114.7M | $112.9M | $98.1M | $86.8M | $83.8M |
| Total assets | $134.9M | $132.5M | $122.4M | $130.5M | $157.5M |
| Accounts payable | $4.07M | $1.19M | $1.3M | $1.15M | $1.94M |
| Short-term debt | $4.01M | $5.35M | $7.82M | $5.32M | $5.24M |
| Deferred revenue | $16.2M | $15.8M | $14.8M | $15.2M | $17.2M |
| Total current liabilities | $36.6M | $35.9M | $36.2M | $33.4M | $40.4M |
| Long-term debt | $75M | $59.1M | $31.1M | $18.1M | $23.4M |
| Deferred revenue, non-current | $0.00 | $220K | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $84.3M | $65.4M | $37.3M | $25M | $31.8M |
| Capital lease obligations | $0.00 | $1.73M | $1.67M | $370K | $1.17M |
| Total liabilities | $120.9M | $101.3M | $73.5M | $58.4M | $72.2M |
| Common stock | $30K | $30K | $30K | $30K | $30K |
| Retained earnings | -$-17.3M | -$-17.06M | -$-30.53M | -$-25.18M | -$-36.11M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | -$-2.38M |
| Total equity | $14M | $31.3M | $49M | $72M | $85.3M |
| Total investments | $0.00 | $1.3M | $0.00 | $0.00 | $0.00 |
| Total debt | $79M | $64.4M | $39M | $23.4M | $28.7M |
| Net debt | $74.9M | $60.2M | $32.3M | -$-1.64M | -$-25.68M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $11.6M | $24.8M | $31M | $31.8M | $37.5M |
| Depreciation and amortization | $7.62M | $6.02M | $5.9M | $5.28M | $6.37M |
| Stock-based compensation | $3.31M | $280K | $940K | $1.2M | $620K |
| Change in working capital | $920K | $3.84M | $1.02M | -$-3.35M | $1.84M |
| Accounts receivable | -$-50K | $1.76M | $2.08M | -$-730K | $340K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $170K | -$-110K | $180K | -$-590K | $0.00 |
| Net cash provided by operating activities | $26.5M | $34.6M | $38.1M | $36.3M | $46.3M |
| Investments in property, plant and equipment | -$-10.71M | -$-15.45M | -$-15.78M | -$-9.84M | -$-5.51M |
| Acquisitions, net | $0.00 | -$-4.83M | $0.00 | $0.00 | -$-3M |
| Net cash used for investing activities | -$-10.71M | -$-20.28M | -$-15.78M | -$-9.84M | -$-8.51M |
| Common stock issued | $130K | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-20.18M | -$-30.95M | -$-19.1M | -$-27.62M | -$-4.14M |
| Dividends paid | -$-10.98M | -$-11.45M | -$-36.37M | -$-20.96M | -$-9.16M |
| Net cash used for financing activities | -$-15.84M | -$-16.76M | -$-40.71M | -$-55.58M | -$-18.16M |
| Net change in cash | -$-90K | -$-2.42M | -$-18.37M | -$-29.34M | $19.7M |
| Cash at end of period | $4.14M | $4.23M | $6.65M | $25M | $54.4M |
| Operating cash flow | $26.5M | $34.6M | $38.1M | $36.3M | $46.3M |
| Capital expenditure | -$-10.71M | -$-15.45M | -$-15.78M | -$-9.84M | -$-5.51M |
| Free cash flow | $15.7M | $19.2M | $22.3M | $26.4M | $40.8M |
Line items
Line items
Line items
About NRC Health
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.
- CEO
- Trent Green
- Employees
- 357
- Beta
- 0.38
Explore
Frequently asked questions
What is the intrinsic value of NRC Health (NRC)?
NRC Health (NRC) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is NRC undervalued?
NRC trades at a price of $25.16 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.